Immunotherapy plus radiation for cancer
Part of Cancer, Immune system & allergy clinical trials.
This study looks at how well immunotherapy (drugs that help your immune system fight cancer) works when combined with radiation therapy. It aims to understand the benefits, risks, and what factors affect treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed cancer diagnosis (from a biopsy or cell sample)
- You and your doctor plan to use immunotherapy together with radiation as your main treatment
- You must have at least one tumor that can be measured on scans
- Your organs (such as liver, kidneys, and blood cells) need to be working well enough based on lab tests
- You must agree to take part, sign a consent form, and come back for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy drugs (like checkpoint inhibitors) work for different cancers. If you are already planning to receive this type of treatment, researchers want to track your outcomes and see how you do over time.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.